AI Emotion-Regulating Wearable MoodSync Receives FDA Class II Medical Device Approval: Closed-Loop Neural Stimulation for Anxiety Relief
Emotion tech company NeuroCalm's AI emotion-regulating wearable MoodSync receives FDA Class II medical device approval, monitoring skin conductance and heart rate variability in real time to assess anxiety states and automatically applying transcutaneous vagus nerve stimulation, reducing generalized anxiety disorder symptom scores by 38% in clinical trials.
AI Emotion-Regulating Wearable MoodSync Receives FDA Approval
Emotion tech company NeuroCalm announced on September 1 that its AI emotion-regulating wearable MoodSync received FDA Class II medical device approval. MoodSync is worn around the neck and monitors the user's autonomic nervous system status in real time through skin conductance sensors and optical heart rate sensors. When the AI model determines the user has entered an anxious state, it automatically intervenes with transcutaneous vagus nerve stimulation (tVNS).
The clinical trial enrolled 240 patients with generalized anxiety disorder. After 12 weeks, the MoodSync group's symptom scores (GAD-7 scale) decreased by an average of 38%, compared to 12% in the control group. MoodSync is priced at approximately $450 with a $29/month AI analysis subscription. The controversy it raises: whether long-term reliance on devices for emotional regulation may weaken humans' autonomous emotional regulation capacity.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.